Potential Predictive Biomarkers Identified for Perioperative Nivolumab in Lung Cancer
Researchers identify potential predictive biomarkers for perioperative nivolumab therapy benefit in resectable non-small cell lung cancer based on the CheckMate 77T trial.
- Potential predictive biomarkers for perioperative nivolumab therapy in non-small cell lung cancer have been identified.
- Findings derive from evaluable participants in the CheckMate 77T clinical trial.